News

News and Press Releases
About the CF Foundation | CFTR Modulators FDA Expands Use of Orkambi® to Children Ages 6 to 11 With CF

The U.S. Food and Drug Administration (FDA) approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 6 to 11, who have two copies of the F508del mutation.

| 2 min read
CFTR Modulators FDA Does Not Approve Ivacaftor for Some Rare Mutations of Cystic Fibrosis

The U.S. Food and Drug Administration (FDA) has decided not to approve the use of ivacaftor (Kalydeco®) to treat people with cystic fibrosis ages 2 and older who have one of 23 rare CF mutations, known as “residual function” mutations. 

| 2 min read